Published in Exp Hematol on August 01, 2003
Imatinib in KIT-negative Systemic Mastocytosis | NCT01297777
IgE and mast cells in allergic disease. Nat Med (2012) 3.14
Mast cells and mastocytosis. Blood (2008) 2.32
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005) 1.83
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood (2005) 1.58
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol (2008) 1.25
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med (2008) 1.10
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol (2009) 1.06
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn (2006) 1.05
Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis (2005) 1.03
mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood (2011) 0.99
Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother (2013) 0.91
Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia (2012) 0.88
Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol (2011) 0.87
Mastocytosis. Chem Immunol Allergy (2010) 0.87
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One (2014) 0.86
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica (2013) 0.86
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol (2013) 0.86
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One (2012) 0.85
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia (2015) 0.85
Retracted Mast cells mediate hyperoxia-induced airway hyper-reactivity in newborn rats. Pediatr Res (2010) 0.84
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res (2007) 0.83
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica (2011) 0.83
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica (2014) 0.82
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia (2015) 0.78
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol (2010) 0.78
Selective RNAi-mediated inhibition of mutated c-kit. J RNAi Gene Silencing (2009) 0.77
NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy (2012) 0.77
Eosinophilia in mast cell disease. Immunol Allergy Clin North Am (2014) 0.77
Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation. Cell Death Dis (2012) 0.76
Systemic mastocytosis with skeletal involvement: a case report and review of the literature. Clin Cases Miner Bone Metab (2009) 0.76
CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1. Sci Rep (2013) 0.76
Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells. PLoS One (2012) 0.76
Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia. BMC Hematol (2014) 0.75
Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. Am J Blood Res (2014) 0.75
Disruption of c-Kit Signaling in Kit(W-sh/W-sh) Growing Mice Increases Bone Turnover. Sci Rep (2016) 0.75
E2A Antagonizes PU.1 Activity through Inhibition of DNA Binding. Biomed Res Int (2016) 0.75
Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2016) 0.75
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget (2016) 0.75
Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol (2002) 20.87
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol (2006) 6.64
IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol (2010) 3.04
Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med (2006) 3.00
Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol (2002) 2.95
Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol (2005) 2.54
Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis (2006) 2.52
Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A (2010) 2.27
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol (2002) 2.19
Vibratory Urticaria Associated with a Missense Variant in ADGRE2. N Engl J Med (2016) 2.09
MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res (2007) 2.08
Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med (2012) 2.08
Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol (2004) 2.02
Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol (2010) 1.98
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol (2007) 1.96
Systemic mastocytosis. Annu Rev Med (2004) 1.74
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Deer antler base as a traditional Chinese medicine: a review of its traditional uses, chemistry and pharmacology. J Ethnopharmacol (2012) 1.63
4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol (2003) 1.61
Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma (2005) 1.61
Kikuchi's disease: case report and systematic review of cutaneous and histopathologic presentations. J Am Acad Dermatol (2008) 1.60
Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer (2009) 1.60
Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol (2003) 1.59
Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol (2007) 1.57
Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood (2004) 1.56
Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol (2003) 1.54
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood (2003) 1.54
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol (2007) 1.52
Prevention of F-actin assembly switches the response to SCF from chemotaxis to degranulation in human mast cells. Eur J Immunol (2013) 1.47
Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood (2007) 1.45
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41
Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci U S A (2011) 1.40
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res (2003) 1.39
Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit. J Biol Chem (2005) 1.36
In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis (2007) 1.35
Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol (2006) 1.34
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol (2007) 1.33
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology (2005) 1.32
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood (2003) 1.32
The phospholipase C gamma 1-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J Biol Chem (2003) 1.32
Activation and function of the mTORC1 pathway in mast cells. J Immunol (2008) 1.31
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med (2003) 1.28
Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J (2005) 1.28
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol (2010) 1.27
5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol (2006) 1.26
Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. Cell Signal (2007) 1.21
Determination of protein phosphorylation in Fc epsilon RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J Immunol Methods (2002) 1.21
Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol (2006) 1.21
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica (2010) 1.19
The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev (2007) 1.19
Silica-directed mast cell activation is enhanced by scavenger receptors. Am J Respir Cell Mol Biol (2006) 1.18
Disappearance of the budding yeast Bub2-Bfa1 complex from the mother-bound spindle pole contributes to mitotic exit. J Cell Biol (2006) 1.18
5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol (2006) 1.17
Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood (2007) 1.17
Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol (2008) 1.16
Growth of human mast cells from bone marrow and peripheral blood-derived CD34+ pluripotent progenitor cells. Methods Mol Biol (2006) 1.15
Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin Immunol (2004) 1.15
IgE(+), Kit(-), I-A/I-E(-) myeloid cells are the initial source of Il-4 after antigen challenge in a mouse model of allergic pulmonary inflammation. J Allergy Clin Immunol (2002) 1.14
Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem (2010) 1.14
Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release. Cell Signal (2008) 1.12
Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol (2011) 1.09
Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood (2002) 1.09
Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther (2007) 1.08
Impulse oscillometry in the evaluation of diseases of the airways in children. Ann Allergy Asthma Immunol (2011) 1.06
IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol (2011) 1.04
Stem cell factor programs the mast cell activation phenotype. J Immunol (2012) 1.03
The high-affinity immunoglobulin-E receptor (FcepsilonRI) is endocytosed by an AP-2/clathrin-independent, dynamin-dependent mechanism. Traffic (2006) 1.03
Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations. Am J Dermatopathol (2013) 1.02
Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am (2003) 1.01
The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol (2004) 1.01
Factors affecting the determination of threshold doses for allergenic foods: how much is too much? J Allergy Clin Immunol (2002) 1.01
Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide. J Biol Chem (2004) 1.01
Clinical overview of cutaneous features in hypereosinophilic syndrome. Curr Allergy Asthma Rep (2012) 1.00
KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood (2011) 0.99
Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol (2003) 0.99
Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci (2010) 0.99
mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood (2011) 0.99
FcepsilonRI- and Fcgamma receptor-mediated production of reactive oxygen species by mast cells is lipoxygenase- and cyclooxygenase-dependent and NADPH oxidase-independent. J Immunol (2007) 0.98
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation. J Infect Dis (2007) 0.98
Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology (2003) 0.97
Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy (2012) 0.97
Mast cell-derived proteases control allergic inflammation through cleavage of IgE. J Allergy Clin Immunol (2007) 0.97
Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunol Res (2009) 0.96
Anaphylaxis: acute treatment and management. Chem Immunol Allergy (2010) 0.96
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica (2008) 0.96
History and classification of anaphylaxis. Novartis Found Symp (2004) 0.95